Tag Archives: ARQL

Top 10 Biotech Stocks To Own For 2018

Its time for the final push.

With only a handful of trading weeks remaining in 2017, little stands in the way of higher prices.

This years stock market melt-up has produced a long list of incredible winners. The FAANGs, semiconductors, and other big tech stocks have helped fuel the rally. Weve also had multiple chances to profit from the big biotech comeback and the rebirth of homebuilder....More>>>

Top Medical Stocks To Watch Right Now

This Top Pick for 2017 may very well have the best and broadest early-stage oncology pipeline with 12 drug development candidates, suggests Jay Silverman, editor The Medical Technology Stock Letter.

Incyte (INCY) is poised for a strong performance in 2017 that will be driven by three major catalysts.

The first is that the firm’s drug Jakafi will continue to be a compelling....More>>>

Hot Biotech Stocks To Invest In 2018

Bio-Techne Corp (NASDAQ:TECH) files its latest 10-K with SEC for the fiscal year ended on June 30, 2017. Bio-Techne Corp and is a biotechnology company which develops, manufactures and sells biotechnology reagents, instruments and clinical diagnostic products. Bio-Techne Corp has a market cap of $4.5 billion; its shares were traded at around $120.62 with a P/E ratio of 62.16 and P/S ratio of 8.35.....More>>>

Best Biotech Stocks To Buy Right Now

Spark Therapeutics (NASDAQ: ONCE) is a primary gene therapy company to address patients suffering from inherited retinal disease (IRD), hemophilia and neurodegenerative diseases. The company presented the cumulative 1-year follow-up Phase 1/2 data of SPK-9001 infusion for the treatment of hemophilia B and preliminary on SPK-8011 Phase 1/2 dose-escalation clinical trial in hemophilia A at the American....More>>>

Top Biotech Stocks To Buy Right Now

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication.

Welcome to another edition of “3 Things In Biotech” a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.

Shire enters the home stretch with its newer formulation of asparaginase

Company: Shire....More>>>

Top 5 Biotech Stocks To Watch For 2019

The stock market finished mixed on Tuesday, and although the Dow Jones Industrials still finished with a loss of more than 100 points, other major market benchmarks finished very close to the unchanged level on the day. Geopolitical pressure continued to hurt investor sentiment, and some bad news on the earnings front also cast a pall on trading during the regular session. Yet some stocks managed....More>>>

Top Biotech Stocks To Buy Right Now

What happened

Shares of Agenus Inc (NASDAQ:AGEN), a biopharmaceutical company developing cancer therapies, had fallen about 14.5% as of 3:20 p.m. EST on Wednesday. Investors weren’t too thrilled about its cancer vaccine’s recent clinical trial failure.

So what

The Prophage G-200 vaccine involved using a patient’s own cancer cells to direct a prolonged immune....More>>>

Hot Biotech Stocks To Buy Right Now

On Tuesday, Baird predicted that Gilead Sciences (GILD) will miss earnings forecasts when it releases its financials on April 28. Barclays’ Geoff Meacham and team, however, foresee an earnings beat from Gilead and Amgen (AMGN) as well, but are more cautious on Biogen (BIIB) and Celgene (CELG). They explain why:

Reuters

Large-Cap Biotechs Strength in Gilead and Amgen. We think....More>>>

Top 10 Biotech Stocks To Buy Right Now

The Dow Jones Industrial Average came close to hitting 20,000, but fell short again…nearly four weeks after Barron’s wrote about the possibility in a cover story on Dec. 10.

Getty Images

The S&P 500 rose 0.4% to 2,276.98 today, a record high. The Nasdaq Composite, meanwhile, gained 0.6% to 5,521.06, also a record. The Dow Jones Industrial Average advanced 64.51 points,....More>>>

Hot Tech Stocks To Invest In Right Now

After meeting with Gilead Sciences’ (GILD) President and incoming CEO John Milligan, UBS analyst Matthew Roden and team see a “re-energized” Gilead. They explain:

Earlier this week, we had the opportunity to host John Milligan, President and incoming CEO of Gilead, for a group dinner and other investor meetings. Topics of discussion were wide-ranging, and included corporate....More>>>